Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivanicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.83 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.83 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.83 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.83 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivanicline SCHEMBL6260928 | 1.00 | CHRNB2 (0.83) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL29423002 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL120435 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL7743987 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL120434 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL29379231 | 0.91 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL5925802 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL5925808 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL5925837 | 0.83 | KMT2A (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Rivanicline SCHEMBL5925845 | 0.83 | KMT2A (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | EYA3, RB1, ALDH1A2 | CHRNB2 63/4885CHRNA4 353/4885CHRNB4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.